Shona Ghosh on LinkedIn: Generative AI startup Synthesia in talks with US fund Accel to raise funds

The platform will leverage de-identified data on over 200 million patients to fine-tune models relevant to several verticals including marketing, drug discovery and clinical trials within a pharmaceutical company. In the new era of GenAI, Synthetica Bio is enabling biopharma companies to use AI responsibly, initially serving commercial teams within this sector. In addition, generative AI is still a nascent technology, and faces significant challenges and uncertainties around ethics, security, reliability, regulation, and more. Data used to train foundation models, for example, reflects historic biases, including around gender and race, and without further research and corrections, will act to accentuate existing systematic biases and discrimination in society. AI-generated content also raises concerns around the spread of deepfakes, counterfeit videos, misinformation, and broader threats to liberal democracy. Moreover, the regulatory landscape is also evolving in real-time, and there are on-going legal challenges in the use of copyrighted data to train models, which in turn threatens future model development and availability.

• As AI technologies progress and become increasingly intricate it becomes imperative to recognize and comprehend their inherent limitations.
• Most startups across this layer are using generative AI to boost operational efficiency, for example by automating repetitive processes and helping with text-based processing and content creation.
• This technology is also predicted to raise global GDP by 7 percent over a decade, making its adoption a vital opportunity to grow the UK economy.
• Driven by recent advancements in large language models (LLMs) and foundation models, hundreds of startups are emerging, leveraging generative models to unleash a wave of new innovations.
• These factors – and others – add to significant on-going uncertainty, and further contribute to the longer-term challenges faced by generative AI startups.

The round also attracted investment from strategic investors including Wells Fargo, Nationwide Building Society, ACT Venture Partners, Terra VC and Neva SGR, the Intesa Sanpaolo bank venture capital company. But c-suites will need to consider how these new technologies will impact their businesses carefully whilst assessing the opportunities for productivity, innovation or access to new markets. This will include areas as varied as the ethics surrounding use of AI, an evolving regulatory environment and the impact on their workforce. GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation.

VC Firms Tap Into ‘Generative AI’ for New Wave of Investments

We believe that over the long term, integration of robust ESG policies make good business sense. All positions within the fund are held on merit – we employ a high-conviction approach and don’t use a benchmark. The Sanlam Global Artificial Intelligence fund looks to invest in companies that are using AI to their benefit.

Our aim is to make the Synthetica Bio platform the central destination for biopharma companies to rapidly and cost-effectively gain actionable insights into data from any source,” added Dr. Dickinson, Executive Chair of Synthetica Bio. It will fuel the development genrative ai of its unique platform and scale its go-to-market team, preparing the company for its full platform launch in the fall. Founded in April 2023, Lumi AI is on an ambitious mission to democratise access to data, insights, and predictive analytics.

London tech firm AutogenAI raises $22.3 million in fresh funding round

… I would rather have my own proposals reviewed by ChatGPT-4 than a lazy human reviewer,” he adds. As the startup continues to gain momentum, its vision of becoming an AI-powered personal data analyst for businesses worldwide is quickly becoming a reality. We’re backing our expert taskforce with the funding to make our ambitions for an AI-enabled country a reality and keep the UK at the front of the pack in this emerging technology. The Taskforce, modelled on the success of the COVID-19 Vaccines Taskforce, will develop the safe and reliable use of this pivotal artificial intelligence (AI) across the economy and ensure the UK is globally competitive in this strategic technology. A tool that generates content based on vast data sets can be a powerful weapon for research, for example in fields such as pharmaceuticals or law. One of the key attributes of a tool is its ability to work 24/7 – unlocking untold productivity.

It also utilises customer data to deliver personalised recommendations and tailored offerings, enhancing satisfaction and retention. This transformative technology drives performance and customer-centricity in the insurance industry. AI21 is among a clutch of AI startups that have benefited from this boom, attracting strong interest from venture capital firms and other investors. This strategic investment underscores Kainos’ dedication to remaining at the forefront of technological advancements. It will focus on advancing breakthroughs in Generative AI understanding, as well as developing cutting-edge solutions, including accelerators, systems, and ecosystem partnerships that address the complex challenges faced by clients. Generative AI technology has been on everyone’s lips in the last few weeks following OpenAI’s release of ChatGPT, which pushes the ability to answer queries or create content to new areas.

Founder of the DevEducation project

Oversight, accountability, and considerations around bias and fairness are crucial to ensure that this technology is harnessed for positive purposes and does not contribute to malicious activities. These advancements in generative AI are made possible by training models on vast amounts of data and leveraging advanced Machine genrative ai Learning algorithms. By analysing and learning from a massive amount of text, these models develop a nuanced understanding of language patterns, context, and human preferences. As AI technologies progress and become increasingly intricate it becomes imperative to recognize and comprehend their inherent limitations.

Luchen Technology, a Chinese start-up specialising in artificial intelligence (AI) training, has closed a Series A round amounting to several hundred million renminbi. Blossom Capital is Europe’s largest dedicated Series A fund, with previous investments including Checkout.com and Moonpay. Insurtech Insights is world’s largest insurtech community, connecting industry executives, entrepreneurs and investors. The chatbot has also left technology companies scrambling to dominate the generative AI market. Since its launch, ChatGPT has garnered interest from people from around the globe for its ability to generate human-like responses to prompts. Gomez was also involved in the publication of a significant research paper that contributed to the development of ChatGPT and similar technologies.

There are other corporates who have formed generative AI funds this year, including mass media group Comcast, which used the technology for the first themed cohort of its Comcast NBCUniversal Lift Labs accelerator. OpenAI, the creator of AI chatbot ChatGPT, closed its corporate venture fund at over $175m last month. The move is a sign of how corporate venturers are increasingly committing cash to generative artificial intelligence, the most recent being Chinese internet group Baidu, which put more than $140m into its own generative AI fund two weeks ago. According to the Financial Times, Generative AI startups have attracted over $21 billion in investment – $11 billion of which were invested in the first quarter of 2023.

#AI is embedded in our everyday life in a manner driven mainly by large centralized tech companies. #SingularityNET is creating a new kind of decentralized, equitable AI economy that drives progress and prosperity to all, not just the elite few. According to a Pitchbook report, VC funding in the sector has been growing over the past few years.

It can also democratise music production, making it more accessible to aspiring artists and enabling them to experiment with innovative sounds and genres. Whilst programme delivery for most strands of the CAP AI project have come to an genrative ai end, we are looking to the future of AI and how we can continue to support AI startups. Both the P4 Precision Medicine Accelerator and UCL MSc Business Consulting Project will continue to support great medtech companies and SMEs.